<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/355h" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/355h/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/355h/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_355h"><akn:num>355h</akn:num><akn:heading>Regulation of certain nonprescription drugs that are marketed without an approved drug application</akn:heading><akn:content><akn:p>§ 355h. Regulation of certain nonprescription drugs that are marketed without an approved drug application(a) Nonprescription drugs marketed without an approved applicationNonprescription drugs marketed without an approved drug application under section 355 of this title, as of March 27, 2020, shall be treated in accordance with this subsection.(1) Drugs subject to a final monograph; category I drugs subject to a tentative final monographA drug is deemed to be generally recognized as safe and effective under section 321(p)(1) of this title, not a new drug under section 321(p) of this title, and not subject to section 353(b)(1) of this title, if—(A) the drug is—(i) in conformity with the requirements for nonprescription use of a final monograph issued under part 330 of title 21, Code of Federal Regulations (except as provided in paragraph (2)), the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and

(ii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to March 27, 2020, has been used to a material extent and for a material time under section 321(p)(2) of this title; or


(B) the drug is—(i) classified in category I for safety and effectiveness under a tentative final monograph that is the most recently applicable proposal or determination issued under part 330 of title 21, Code of Federal Regulations;

(ii) in conformity with the proposed requirements for nonprescription use of such tentative final monograph, any applicable subsequent determination by the Secretary, the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and

(iii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subse</akn:p></akn:content><akn:subsection eId="subsec_355h_a"><akn:num>(a)</akn:num><akn:heading>Nonprescription drugs marketed without an approved application</akn:heading><akn:content><akn:p>(a) Nonprescription drugs marketed without an approved application Nonprescription drugs marketed without an approved drug application under section 355 of this title, as of March 27, 2020, shall be treated in accordance with this subsection.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_b"><akn:num>(b)</akn:num><akn:heading>Administrative orders</akn:heading><akn:content><akn:p>(b) Administrative orders</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_c"><akn:num>(c)</akn:num><akn:heading>Procedure for minor changes</akn:heading><akn:content><akn:p>(c) Procedure for minor changes</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_d"><akn:num>(d)</akn:num><akn:heading>Confidentiality of information submitted to the Secretary</akn:heading><akn:content><akn:p>(d) Confidentiality of information submitted to the Secretary</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_e"><akn:num>(e)</akn:num><akn:heading>Updates to drug listing information</akn:heading><akn:content><akn:p>(e) Updates to drug listing information A sponsor who makes a change to a drug subject to this section shall submit updated drug listing information for the drug in accordance with section 360(j) of this title within 30 calendar days of the date when the drug is first commercially marketed, except that a sponsor who was the order requestor with respect to an order subject to subsection (b)(5)(C) (or a licensee, assignee, or successor in interest of such requestor) shall submit updated drug listing information on or before the date when the drug is first commercially marketed.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_f"><akn:num>(f)</akn:num><akn:heading>Approvals under section 355 of this title</akn:heading><akn:content><akn:p>(f) Approvals under The provisions of this section shall not be construed to preclude a person from seeking or maintaining the approval of an application for a drug under sections 355(b)(1), 355(b)(2), and 355(j) of this title. A determination under this section that a drug is not subject to section 353(b)(1) of this title, is generally recognized as safe and effective under section 321(p)(1) of this title, and is not a new drug under section 321(p) of this title shall constitute a finding that the drug is safe and effective that may be relied upon for purposes of an application under section 355(b)(2) of this title, so that the applicant shall be required to submit for purposes of such application only information needed to support any modification of the drug that is not covered by such determination under this section.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_g"><akn:num>(g)</akn:num><akn:heading>Public availability of administrative orders</akn:heading><akn:content><akn:p>(g) Public availability of administrative orders The Secretary shall establish, maintain, update (as determined necessary by the Secretary but no less frequently than annually), and make publicly available, with respect to orders issued under this section—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_h"><akn:num>(h)</akn:num><akn:heading>Development advice to sponsors or requestors</akn:heading><akn:content><akn:p>(h) Development advice to sponsors or requestors The Secretary shall establish procedures under which sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding may meet with appropriate officials of the Food and Drug Administration to obtain advice on the studies and other information necessary to support submissions under this section and other matters relevant to the regulation of nonprescription drugs and the development of new nonprescription drugs under this section.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_i"><akn:num>(i)</akn:num><akn:heading>Participation of multiple sponsors or requestors</akn:heading><akn:content><akn:p>(i) Participation of multiple sponsors or requestors The Secretary shall establish procedures to facilitate efficient participation by multiple sponsors or requestors in proceedings under this section, including provision for joint meetings with multiple sponsors or requestors or with organizations nominated by sponsors or requestors to represent their interests in a proceeding.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_355h_j"><akn:num>(j)</akn:num><akn:heading>Electronic format</akn:heading><akn:content><akn:p>(j) Electronic format All submissions under this section shall be in electronic format.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>